Jaka jest cena za Jiangsu Recbio Technology Co., Ltd. (2179)

Cena za Jiangsu Recbio Technology Co., Ltd. (2179) wynosi $0.63963115

Jaka jest kapitalizacja rynkowa dla Jiangsu Recbio Technology Co., Ltd. (2179)

Kapitalizacja rynkowa dla Jiangsu Recbio Technology Co., Ltd. (2179) wynosi $339.16M

Jiangsu Recbio Technology Co., Ltd. (2179) Wskaźnik C/WK

Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.

Rok	Wskaźnik P/B	Zmień
Za mało danych dla podanych dat.

Rok

Wskaźnik P/B

Zmień

Za mało danych dla podanych dat.

Firma	Wskaźnik P/B	Różnica wskaźnika P/B	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	6.828	-	US
Argenx SE ARGX.US	7.5116	-	NL
CSL Limited CSL.AX	3.9942	-	AU
Moderna, Inc. MRNA.US	8.2199	-	US
Lonza Group AG LONN.SW	-	-	CH

Firma

Wskaźnik P/B

Różnica wskaźnika P/B

Kraj